DOI QR코드

DOI QR Code

Resolution of Protein-Losing Enteropathy after Congenital Heart Disease Repair by Selective Lymphatic Embolization

  • Kylat, Ranjit I (Department of Pediatrics, The University of Arizona College of Medicine) ;
  • Witte, Marlys H (Department of Surgery, The University of Arizona College of Medicine) ;
  • Barber, Brent J (Department of Pediatrics, The University of Arizona College of Medicine) ;
  • Dori, Yoav (Center for Lymphatic Imaging and Interventions, Children's Hospital of Philadelphia) ;
  • Ghishan, Fayez K (Department of Pediatrics, The University of Arizona College of Medicine)
  • Received : 2018.09.20
  • Accepted : 2019.01.01
  • Published : 2019.11.15

Abstract

With improving survival of children with complex congenital heart disease (CCHD), postoperative complications, like protein-losing enteropathy (PLE) are increasingly encountered. A 3-year-old girl with surgically corrected CCHD (ventricular inversion/L-transposition of the great arteries, ventricular septal defect, pulmonary atresia, postdouble switch procedure [Rastelli and Glenn]) developed chylothoraces. She was treated with pleurodesis, thoracic duct ligation and subsequently developed chylous ascites and PLE (serum albumin ${\leq}0.9g/dL$) and was malnourished, despite nutritional rehabilitation. Lymphangioscintigraphy/single-photon emission computed tomography showed lymphatic obstruction at the cisterna chyli level. A segmental chyle leak and chylous lymphangiectasia were confirmed by gastrointestinal endoscopy, magnetic resonance (MR) enterography, and MR lymphangiography. Selective glue embolization of leaking intestinal lymphatic trunks led to prompt reversal of PLE. Serum albumin level and weight gain markedly improved and have been maintained for over 3 years. Selective interventional embolization reversed this devastating lymphatic complication of surgically corrected CCHD.

Keywords

References

  1. Greenwald DA. Protein-losing gastroenteropathy. In: Feldman M, Friedman L, Brandt L, eds. Sleisenger and Fordtran's gastrointestinal and liver disease. 10th ed. Philadelphia: Saunders, 2016:464-70.
  2. Levitt DG, Levitt MD. Protein losing enteropathy: comprehensive review of the mechanistic association with clinical and subclinical disease states. Clin Exp Gastroenterol 2017;10:147-68. https://doi.org/10.2147/CEG.S136803
  3. Johnson JN, Driscoll DJ, O'Leary PW. Protein-losing enteropathy and the Fontan operation. Nutr Clin Pract 2012;27:375-84. https://doi.org/10.1177/0884533612444532
  4. Mertens L, Hagler DJ, Sauer U, Somerville J, Gewillig M. Protein-losing enteropathy after the Fontan operation: an international multicenter study. PLE study group. J Thorac Cardiovasc Surg 1998;115:1063-73. https://doi.org/10.1016/S0022-5223(98)70406-4
  5. Malcic I, Sauer U, Stern H, Kellerer M, Kuhlein B, Locher D, et al. The influence of pulmonary artery banding on outcome after the Fontan operation. J Thorac Cardiovasc Surg 1992;104:743-7. https://doi.org/10.1016/S0022-5223(19)34745-2
  6. John AS, Johnson JA, Khan M, Driscoll DJ, Warnes CA, Cetta F. Clinical outcomes and improved survival in patients with protein-losing enteropathy after the Fontan operation. J Am Coll Cardiol 2014;64:54-62. https://doi.org/10.1016/j.jacc.2014.04.025
  7. Gleason WA Jr, Roodman ST, Laks H. Protein-losing enteropathy and intestinal lymphangiectasia after superior vena cava--right pulmonary artery (Glenn) shunt. J Thorac Cardiovasc Surg 1979;77:843-6. https://doi.org/10.1016/S0022-5223(19)38186-3
  8. Meadows J, Jenkins K. Protein-losing enteropathy: integrating a new disease paradigm into recommendations for prevention and treatment. Cardiol Young 2011;21:363-77. https://doi.org/10.1017/S1047951111000102
  9. Meadows J, Gauvreau K, Jenkins K. Lymphatic obstruction and protein-losing enteropathy in patients with congenital heart disease. Congenit Heart Dis 2008;3:269-76. https://doi.org/10.1111/j.1747-0803.2008.00201.x
  10. Rychik J, Spray TL. Strategies to treat protein-losing enteropathy. Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu 2002;5:3-11. https://doi.org/10.1053/pcsu.2002.31498
  11. James H, Witte MH, Bernas M, Barber B. Proposal for prevention or alleviation of protein/lymph-losing enteropathy (PLE/LLE) after Fontan circulation treatment of univentricular hearts: restoration of lymph balance with a "lymphatic right-to-left shunt.". Lymphology 2016;49:114-27.
  12. Petersen VP, Hastrup J. Protein-losing enteropathy in constrictive pericarditis. Acta Med Scand 1963;173:401-10. https://doi.org/10.1111/j.0954-6820.1963.tb17423.x
  13. Antonio M, Gordo A, Pereira C, Pinto F, Fragata I, Fragata J. Thoracic duct decompression for proteinlosing enteropathy in failing fontan circulation. Ann Thorac Surg 2016;101:2370-3. https://doi.org/10.1016/j.athoracsur.2015.08.079
  14. Connor FL, Angelides S, Gibson M, Larden DW, Roman MR, Jones O, et al. Successful resection of localized intestinal lymphangiectasia post-Fontan: role of (99m)technetium-dextran scintigraphy. Pediatrics 2003;112(3 Pt 1):e242-7. https://doi.org/10.1542/peds.112.3.e242
  15. Magdo HS, Stillwell TL, Greenhawt MJ, Stringer KA, Yu S, Fifer CG, et al. Immune abnormalities in Fontan protein-losing enteropathy: a case-control study. J Pediatr 2015;167:331-7. https://doi.org/10.1016/j.jpeds.2015.04.061
  16. Muller C, Wolf H, Gottlicher J, Zielinski CC, Eibl MM. Cellular immunodeficiency in protein-losing enteropathy. Predominant reduction of CD3+ and CD4+ lymphocytes. Dig Dis Sci 1991;36:116-22. https://doi.org/10.1007/BF01300099
  17. Goldberg DJ, Dodds K, Avitabile CM, Glatz AC, Brodsky JL, Semeao EJ, et al. Children with protein-losing enteropathy after the Fontan operation are at risk for abnormal bone mineral density. Pediatr Cardiol 2012;33:1264-8. https://doi.org/10.1007/s00246-012-0290-z
  18. Guez D, Nadolski GJ, Pukenas BA, Itkin M. Transhepatic lymphatic embolization of intractable hepatic lymphorrhea. J Vasc Interv Radiol 2014;25:149-50. https://doi.org/10.1016/j.jvir.2013.09.002
  19. Itkin M, Piccoli DA, Nadolski G, Rychik J, DeWitt A, Pinto E, et al. Protein-losing enteropathy in patients with congenital heart disease. J Am Coll Cardiol 2017;69:2929-37. https://doi.org/10.1016/j.jacc.2017.04.023
  20. Latson L. Once more unto the breach: a new treatment paradigm for protein-losing enteropathy. J Am Coll Cardiol 2017;69:2938-40. https://doi.org/10.1016/j.jacc.2017.04.024

Cited by

  1. Update FEBRUARY 2020 vol.18, pp.1, 2020, https://doi.org/10.1089/lrb.2020.29077.fb
  2. Tricuspid atresia: Where are we now? vol.35, pp.7, 2019, https://doi.org/10.1111/jocs.14673